FY2025 Earnings Estimate for NRXP Issued By HC Wainwright

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Equities research analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of NRx Pharmaceuticals in a research note issued on Monday, September 8th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.57) per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2026 earnings at $0.42 EPS.

Other equities research analysts have also issued research reports about the company. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. BTIG Research reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Monday. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Trading Down 3.0%

NASDAQ NRXP opened at $2.88 on Thursday. The business’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $2.55. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01. The firm has a market capitalization of $57.05 million, a PE ratio of -1.29 and a beta of 1.63.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67).

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth $56,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth $61,000. Geode Capital Management LLC raised its position in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Finally, Anson Funds Management LP raised its position in NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after purchasing an additional 993,401 shares in the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.